Animal study · mice and hamsters
Retatrutide cut body weight by 31% in obese mice with MASH
Checked against the paper Animal studyPublished by PepVault
The takeaway
In two obese animal models, retatrutide lowered weight, insulin resistance and liver fat measures, with some lean mass lost along with fat in the mice.
- Kind
- Animal study
- Studied in
- Mice and hamsters
- Published
- 2026
- Journal
- Obesity (Silver Spring)
What they tested
The team tested whether retatrutide improves weight, insulin resistance and liver fat in obese mouse and hamster models of MASH, a form of fatty liver disease.
How the study was done
A preclinical study in mice and hamsters made obese by diet, comparing retatrutide with vehicle, an inactive control solution. Hamsters were treated for 5 weeks.

Model. Individual results vary.
What they found
In mice, retatrutide lowered body weight by 31% against vehicle, with losses in both fat and lean mass and lower food and water intake in the first days, while energy expenditure did not change significantly. The mice also had a lower HOMA-IR, an index of insulin resistance, a lower liver fat score, and less fatty acid, triglyceride and total cholesterol content. In hamsters, retatrutide shifted eating toward plain chow and away from the high fat/cholesterol diet and 10% fructose water, and led to significant weight loss; lean mass was not different after 5 weeks and bone mineral density did not change. Hamsters had lower HOMA-IR, plasma triglycerides and LDL cholesterol, and 50% less liver triglyceride, though the liver tissue score did not improve.
What it doesn’t show
These results come from mice and hamsters, not people. In hamsters, the liver tissue score did not improve even though liver triglycerides fell.
The paper
Briand et al. Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Obesity (Silver Spring). 2026.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.